The tree · Window · Happens to the world · Could be decided within 1 to 5 years
A major drug regulator accepts slowing aging as something a drug can be approved for
Today a drug must target a named disease. There is no approvable indication for slowing aging itself, which is why aging drugs are tested against single diseases and why companies avoid the field. In 2015 the US regulator agreed that one trial could use a composite of age-related diseases as its primary endpoint, which is the precedent; what does not yet exist is guidance saying a drug can be approved, and labelled, for slowing aging. That is what changes what gets funded and trialed.
The test: what counts as it having happened
The US Food and Drug Administration or the European Medicines Agency establishes that slowing aging, extending healthy lifespan, or delaying a composite of age-related diseases is an indication for which a drug can be approved and labelled, by any of: final published guidance saying so; a published regulatory decision that establishes an approval pathway for it; or an actual approval whose label names that indication. Accepting such a composite as a trial endpoint, which the US regulator did in 2015, does not count.
Settled by: The regulator's own published guidance, pathway decision, or approval record
The odds, by how long I live
| baselineto 2071 ± 8 | moderateto 2080 | strongto 2095 | radicalto 2136 | openno deadline |
|---|---|---|---|---|
| 55% | 60% | 70% | 85% | 90% |
Each column is a different guess at how long I live, from current trends (baseline) to open-ended. The number is the chance this happens before that deadline, assuming everything it depends on happens first. As of September 8th, 2026.
Why these numbers: The 2015 composite-endpoint precedent and a growing field make guidance within forty-five years somewhat more likely than not; every added decade of trials and lobbying raises it.
What this one is worth
Nothing. The headline number does not rest on this step at any remove, so however it turns out, the chance that I live and work off Earth does not change. That is not a judgement that it does not matter. It is what the tree says: this step feeds a tier above the one the headline asks about, or sits beside the equation rather than in it.
What the ledger says about this step
- Forty-one steps had their criteria tightened so that two readers would agree when each has happened, with no number moved for that alone 2026-09-20 The tree itself changed
The last 3 checks
Once a week the tree is read against the news, node by node, against the test above. Open a line to see what that week held. Every check ever made on this node is on the Radar page.
-
2026-11-01 Nothing new
No FDA or EMA guidance, pathway decision or approval naming aging as an indication was found. Only conference remarks from FDA officials at ARDD 2026 and commentary (a Science policy piece dated October 1st, 2026) turned up, which are not the criterion.
-
2026-10-25 Nothing new
Neither the FDA nor the EMA has published guidance or a pathway for aging as an indication. At the ARDD conference in 2026 an FDA official said aging will be a topic in the updated Focus Areas of Regulatory Science report, due early in fiscal 2027, which is a planning document, not final guidance.
-
2026-10-18 Nothing new
No guidance, pathway decision or approval names aging as an indication. FDA's plan to feature aging in its Focus Areas of Regulatory Science update (tentatively fiscal 2027) is a plan, and TAME's 2015 composite-endpoint agreement is the excluded case.
Revisions
| Date | Field | From | To | Why |
|---|---|---|---|---|
| 2026-09-19 | resolution | the regulator must publish guidance naming the indication | any of final guidance, a published pathway decision, or an approval whose label names the indication | Step 27 outside-model review, item 35 (docs/reviews/2026-09-19-rulings.md): requiring a particular guidance document measured administrative form, and a first approval without prior guidance would have resolved this node's child while it stayed open. Decided September 19th, 2026. |
Notes
Checked September 8th, 2026 against the trial's own design papers and the National Institute on Aging's page on regulator review of aging-related applications: the regulator approved the trial's composite design and the trial 'holds the potential' to lead to aging being considered an indication, which confirms that no approvable indication exists yet.
Think this estimate is wrong?
Here's how to tell me, and
what happens next.
The record itself is data/W-window.toml in the public repository.